By Sabela Ojea
Shares of Sanuwave Health climbed on the path toward their highest close in almost three years after the company guided for further growth in 2025.
The stock gained 13%, to $36.20, in Friday afternoon trading. Shares are up 57% year to date.
The developer of patented noninvasive, biological response activating devices said it expects revenue of $48 million to $50 million for 2025 as it guided for a first-quarter top-line performance between $8.4 million and $9 million.
In 2024, the company had reported revenue of $32.6 million.
"We are confident that our revenue pipeline is stronger than it has ever been and have been ramping up our sales force and sales strategy to meet this opportunity and to effectively manage the larger customers with whom we continue to engage," Chief Executive Morgan Frank said.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
March 21, 2025 15:05 ET (19:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。